Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
EORTC HQ, Brussels, Belgium
EORTC HQ, Brussels, Belgium
Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Corresponding Author: Martin J. van den Bent, MD, Neuro-Oncology Unit, Brain Tumor Center at Erasmus MC Cancer Institute, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands ([email protected]).
Revised January 31, 2022
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
